BioMarin amends Phase III of hemophilia A gene therapy

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) increased enrollment in a Phase III trial of valoctocogene roxaparvovec (formerly BMN 270) to treat severe hemophilia A and reported long-term data from a Phase I/II trial of the gene therapy in the indication.

BioMarin increased enrollment to 130 patients from 40 in the Phase III

Read the full 498 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE